Hepatitis B and hepatitis C are caused by two distinct viruses that infect the liver, but they spread in different ways and behave differently once inside the body. Hepatitis B (HBV) is a DNA virus transmitted through blood, sexual contact, and from mother to child during birth. Hepatitis C (HCV) is an RNA virus spread almost exclusively through blood-to-blood contact. Understanding these differences matters because it affects who’s at risk, how the infections progress, and what can be done about them.
The Viruses Behind Each Infection
HBV and HCV are fundamentally different organisms that happen to target the same organ. HBV carries a small, partially double-stranded DNA genome and replicates through an unusual process: it first converts its DNA into an RNA intermediate, then reverse-transcribes that RNA back into DNA inside the liver cell. This creates a stable form of viral DNA that lodges in the cell’s nucleus and acts as the master template for producing new virus. That stable DNA template is one reason HBV can persist in the body for decades.
HCV, by contrast, is a single-stranded RNA virus with a genome roughly three times the size of HBV’s. When it enters a liver cell, its RNA is immediately used to produce a large protein that gets chopped into ten functional pieces by cellular and viral enzymes. HCV never integrates into the cell’s DNA the way HBV’s template does, which is part of why modern antiviral drugs can eliminate it so effectively.
Both viruses enter liver cells through specific receptors on the cell surface. HCV in particular requires multiple surface molecules to gain entry, making the liver its almost exclusive target.
How Hepatitis B Spreads
HBV is present at high concentrations in blood and at lower but still significant levels in semen, vaginal fluids, saliva, and breast milk. A highly infectious carrier can have billions of viral copies per milliliter of blood, with saliva and nasal fluids also carrying detectable virus. Urine typically contains 100 to 1,000 times less virus than blood, but still enough to be measurable.
This wide distribution across body fluids is why HBV spreads through several routes:
- Sexual contact: HBV is efficiently transmitted through unprotected sex, making it one of the most common sexually transmitted infections worldwide.
- Blood exposure: Sharing needles, accidental needlesticks in healthcare settings, and unscreened blood transfusions all carry risk.
- Mother to child: Without preventive treatment, mothers with high viral loads transmit HBV to their newborns 70% to 90% of the time. Even mothers with lower viral loads pass the virus in 10% to 40% of cases.
- Household contact: Because HBV survives on surfaces and is present in saliva, shared razors, toothbrushes, or open wounds can transmit the virus within households.
The risk of mother-to-child transmission is so significant that pregnant women with HBV DNA levels above 200,000 IU/mL may transmit the virus even when the infant receives the full vaccine series plus protective antibodies at birth. In those cases, antiviral treatment during pregnancy helps reduce the risk.
How Hepatitis C Spreads
HCV is a bloodborne virus, and nearly all transmission involves direct blood-to-blood contact. The most common routes, according to the World Health Organization, are sharing needles and syringes among people who inject drugs, reuse or inadequate sterilization of medical equipment (particularly syringes and needles), and transfusion of unscreened blood products.
Sexual transmission of HCV does occur, but it is far less efficient than with HBV. The risk is highest during sexual practices that involve exposure to blood, particularly among men who have sex with men and people with multiple partners. For monogamous heterosexual couples where one partner has HCV, the transmission risk per year is very low. Mother-to-child transmission is also possible but less common than with HBV.
Before widespread blood screening was introduced in the early 1990s, transfusions were a major source of HCV infection. Today, injection drug use accounts for the majority of new cases in high-income countries.
Why Some Infections Become Chronic
One of the most important differences between these viruses is what happens after the initial infection. Your age at the time of HBV exposure dramatically changes the outcome. About 90% of infants infected with HBV become chronic carriers, and roughly 30% of children infected between ages one and five develop chronic infection. Adults, by contrast, clear the virus on their own about 95% of the time.
This age-dependent pattern exists because an infant’s immune system doesn’t mount the same aggressive response to HBV that an adult’s does. The virus essentially establishes itself before the immune system learns to recognize it as a threat. By the time the immune system matures, the virus is deeply entrenched in the liver.
HCV follows a different pattern that doesn’t depend on age. Regardless of when you’re exposed, an estimated 55% to 85% of people who contract HCV will develop chronic infection. The remaining 15% to 45% clear the virus spontaneously within six months, often without ever knowing they were infected. Researchers aren’t entirely sure why some people clear HCV and others don’t, though genetic factors and the strength of the initial immune response play a role.
What Chronic Infection Does to the Liver
Both chronic HBV and chronic HCV cause ongoing inflammation in the liver. Over years or decades, this persistent inflammation leads to scarring (fibrosis), which can progress to cirrhosis and eventually liver cancer. The timeline varies widely. Some people live with chronic hepatitis for decades with minimal liver damage, while others develop serious complications within 10 to 20 years.
A key challenge with both viruses is that chronic infection often produces no symptoms for years. Many people don’t know they’re infected until liver damage is already advanced, which is why screening recommendations exist for people with known risk factors.
Prevention and Treatment Outlook
Hepatitis B has an effective vaccine that provides over 90% protection in healthy adults who complete the full series. Long-term studies show that at least 90% of vaccinated people still have evidence of protection 30 years later. Universal childhood vaccination programs have dramatically reduced HBV rates in countries where they’ve been implemented. For chronic HBV, antiviral medications can suppress the virus and slow liver damage, but they rarely eliminate it completely because of that stable DNA template lodged in liver cells.
There is no vaccine for hepatitis C, but treatment has transformed in recent years. Modern direct-acting antiviral medications cure more than 95% of people with chronic HCV, regardless of viral strain, the severity of liver scarring, or HIV status. Most treatment courses last about 12 weeks and are taken as oral pills. Even people with compensated cirrhosis typically achieve cure rates above 95%. This is a striking shift from older treatments that were less effective and caused significant side effects.
The practical difference: HBV is best addressed through prevention (vaccination), while HCV is increasingly managed through cure after diagnosis. Both strategies depend on people knowing their status, which makes testing the critical first step for anyone with potential exposure.